Ravgen and Myriad in patent dispute over DNA testing tech

Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circuit restores two Illumina DNA patents in blow to Roche

19 March 2020 The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.

Americas

Illumina, Roche accused of infringing genetic testing patents

7 December 2020 Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.

More on this story

Americas

Fed Circuit restores two Illumina DNA patents in blow to Roche

19 March 2020 The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.

Americas

Illumina, Roche accused of infringing genetic testing patents

More on this story

Americas

Fed Circuit restores two Illumina DNA patents in blow to Roche

19 March 2020 The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.

Americas

Illumina, Roche accused of infringing genetic testing patents